Pregnancy Clinical Trial
— 2GetherOfficial title:
Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens
Verified date | November 2018 |
Source | Centers for Disease Control and Prevention |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will evaluate a multi-component, clinic-based intervention aimed at increasing
dual protection strategy selection and adherence among young African American females at an
urban family planning clinic. Dual protection is the use of contraceptive strategies to
prevent both unintended pregnancy (UIP) and sexually transmitted infections (STIs). This is
an unblinded randomized controlled trial; participants will either get the interactive
multimedia platform focused on DP strategies with intervention arm counseling or the standard
of care arm counseling.
The study will recruit 710 African American females aged 14-19 who are attending the Grady
Health System (GHS) Teen Services Clinic (TSC) in Atlanta, Georgia, for reproductive health
care.
The trial will recruit and enroll 710 young women presenting to the clinic for clinical care
who have the following characteristics:
- self-identify as African American,
- 14-19 years of age,
- have had vaginal sex with a male partner in the past 6 months,
- HIV-negative by self-report,
- not pregnant,verified by urine pregnancy test,
- no desire to be pregnant in next 12 months,
- plan to stay in the Atlanta area for the next year,
- are willing to provide contact information, and
- were not previously enrolled in the pilot study of this intervention.
Those enrolled will be in the study for 12 months. Young women who are eligible and give
written consent or assent for study participation will be enrolled. Half will be randomized
to the control arm, half to the intervention arm.
1. Control arm (standard of care) includes individual clinical care and standard of care
counseling consistent with protocols at the TSC, with study visits for data collection
at enrollment, 6 months, and 12 months, during which any medical care or counseling that
they would normally get will also be provided. Control arm participants will also get
telephone calls from clinic staff to update their contact information and remind them of
upcoming visits at 3 weeks and 5 months after the enrollment visit, and at 3 weeks and 5
months after the 6 month visit.
2. Intervention arm, consisting of the following intervention components:
1. Enrollment visit
- A culturally-appropriate interactive multimedia platform focused on DP
strategies and designed to prepare the individual for selection of a DP
strategy.
- Individual intervention arm counseling to select the DP strategy that is best
suited for the participant (by a clinic health care provider).
- Individual intervention arm counseling to build skills for correct and
consistent use of the selected DP strategy (by a nurse educator (NE)).
2. Booster counseling via phone at about 3 weeks and 5 months after the enrollment
visit, and at about 3 weeks and 5 months after the 6 month visit (by an NE).
3. 6 month visit
- An abbreviated version of the interactive multimedia platform focused on dual
protection strategies and strategy adherence.
- Individual intervention arm counseling to reinforce skills for correct and
consistent use of the DP strategy (by an NE).
At the final study visit at 12 months there is no difference between the counseling provided
to the two groups; participants in both arms will receive the clinic standard of care.
Participants in both arms of the study will follow the same data collection procedures
throughout the study:
- At all three study visits, participants in both arms will receive urine pregnancy and
STI tests and complete an audio computer assisted self-interview (ACASI) questionnaire.
- At 3 and 9 months after enrollment, participants in both arms will receive a data
collection call with administration of a telephone questionnaire.
Throughout the study, all participants will be encouraged to come in for evaluation if they
have any concerns. Any data from pregnancy or STI testing at these interim clinic visits will
be later collected via chart review. If participants seek reproductive health care at other
facilities during the study period, records will be requested with participant permission,
and data from pregnancy or STI testing at these outside clinic visits will be collected via
review of records received.
We will examine the efficacy of the intervention arm relative to control arm across the
following primary behavioral and biologic outcomes over the 12 months of follow-up:
1. Self-reported dual protection strategy selection
2. Self-reported dual protection strategy adherence
3. Incidence of pregnancy or infection with chlamydia, gonorrhea or trichomonas (as
confirmed by laboratory testing)
A small pilot study was be conducted prior to the initiation of enrollment in the main study.
Status | Completed |
Enrollment | 709 |
Est. completion date | August 2018 |
Est. primary completion date | August 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 14 Years to 19 Years |
Eligibility |
Inclusion Criteria: - female, - self-identify as African American, - 14-19 years of age, - present to clinic on date of potential enrollment for clinical care, - has had vaginal sex with a male partner at least once in the past 6 months, - HIV-negative by self-report, - not currently pregnant (verified by urine pregnancy test), - desire to avoid pregnancy for at least 12 months, - plan to be in the Atlanta area for the next 12 months, - competent to participate in consenting or assenting process per recruiter evaluation, - willing to provide contact information, and - not previously enrolled in the pilot study of this intervention. Exclusion Criteria: - pregnant - HIV positive |
Country | Name | City | State |
---|---|---|---|
United States | Grady Health System Teen Services Clinic | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Centers for Disease Control and Prevention | Emory University, Grady Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Participant selection of an effective dual protection (DP) strategy | Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following: Abstinence from vaginal sex; Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use; Consistent condom use only |
6 months | |
Primary | Participant report of adherence to DP strategy | By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes: Whether or not DP strategy was used at last sex Whether or not DP strategy was used consistently during last 3 month time period Estimated proportion of time adherent to DP strategy over last 3 months |
3 months | |
Primary | Time to first biologic event (pregnancy or diagnosis with STI) in participants | Measured by date of positive lab test ("biologic event" refers to a positive pregnancy test or diagnosis with chlamydia, gonorrhea or trichomonas infection). | Within 12 month period following enrollment | |
Primary | Incidence of pregnancy and sexually transmitted infections (STIs) | Includes the proportion of participants with a lab-confirmed diagnosis of pregnancy or lab-confirmed diagnosis with infection with chlamydia, gonorrhea or trichomonas within the 12 month follow-up period (testing either performed at study site clinic and documented at study visits and via chart review, or diagnosed by outside labs with documentation obtained via release of information procedures) | Within 12 month period following enrollment | |
Primary | Participant selection of an effective dual protection (DP) strategy | Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following: Abstinence from vaginal sex; Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use; Consistent condom use only |
12 months | |
Primary | Participant report of adherence to DP strategy | By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes: Whether or not DP strategy was used at last sex Whether or not DP strategy was used consistently during last 3 month time period Estimated proportion of time adherent to DP strategy over last 3 months |
6 months | |
Primary | Participant report of adherence to DP strategy | By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes: Whether or not DP strategy was used at last sex Whether or not DP strategy was used consistently during last 3 month time period Estimated proportion of time adherent to DP strategy over last 3 months |
9 months | |
Primary | Participant report of adherence to DP strategy | By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes: Whether or not DP strategy was used at last sex Whether or not DP strategy was used consistently during last 3 month time period Estimated proportion of time adherent to DP strategy over last 3 months |
12 months | |
Primary | Participant selection of an effective dual protection (DP) strategy | Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following: Abstinence from vaginal sex; Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use; Consistent condom use only |
At enrollment visit | |
Secondary | Participant level of reproductive health knowledge (percentage correct of knowledge questions) | Knowledge about contraceptives and STIs, as measured by correct answers to knowledge questions on ACASI questionnaires. | 6 months | |
Secondary | Participant intention to use DP strategy | Whether or not participant self-reports intention to use an effective DP strategy in the future, as measured by responses on ACASI questionnaires. | 6 months | |
Secondary | Participant reproductive health self-efficacy | Whether or not participant reported high self-efficacy for condom use, contraceptive use, and communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires. | 6 months | |
Secondary | Participant report of STI testing | Frequency of self-reported STI testing by participant and partner(s) and result-sharing with partner(s), as measured by responses to ACASI questionnaires. | 6 months | |
Secondary | Participant report of partner communication | Self-reported frequency of communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires. | 6 months | |
Secondary | Participant level of reproductive health knowledge (percentage correct of knowledge questions) | Knowledge about contraceptives and STIs, as measured by correct answers to knowledge questions on ACASI questionnaires. | 12 months | |
Secondary | Participant intention to use DP strategy | Whether or not participant self-reports intention to use an effective DP strategy in the future, as measured by responses on ACASI questionnaires. | 12 months | |
Secondary | Participant report of STI testing | Frequency of self-reported STI testing by participant and partner(s) and result-sharing with partner(s), as measured by responses to ACASI questionnaires. | 12 months | |
Secondary | Participant reproductive health self-efficacy | Whether or not participant reported high self-efficacy for condom use, contraceptive use, and communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires. | 12 months | |
Secondary | Participant report of partner communication | Self-reported frequency of communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Terminated |
NCT02546193 -
Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction
|
N/A |